Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 7, 2002, Pages 670-671

  Keller, Josbert J ^a   Offerhaus, G Johan A ^a   Hylind, Linda M ^b   Giardiello, Francis M ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SULINDAC;

ADENOMATOUS POLYP; APOPTOSIS; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; EPITHELIUM CELL; FAMILIAL POLYPOSIS; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM; RECTUM BIOPSY; SIGMOIDOSCOPY;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; APOPTOSIS; BIOPSY, NEEDLE; COLONIC NEOPLASMS; EPITHELIUM; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RECTUM; REFERENCE VALUES; SULINDAC; TREATMENT OUTCOME;

EID: 0036310589     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Inward growth of colonic adenomatous polyps
2. Phase 1 and phase 2 proliferative lesions of colonic epithelial cells in diseases leading to colonic cancer
3. Inhibition of apoptosis during development of colorectal cancer
4. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
5. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac
6. Primary chemoprevention of familial adenomatous polyposis with sulindac